NO892319L - Fremgangsmaate for aa inhibere tilstroemning av leucocytter til organer under sepsis eller annen trauma. - Google Patents

Fremgangsmaate for aa inhibere tilstroemning av leucocytter til organer under sepsis eller annen trauma.

Info

Publication number
NO892319L
NO892319L NO89892319A NO892319A NO892319L NO 892319 L NO892319 L NO 892319L NO 89892319 A NO89892319 A NO 89892319A NO 892319 A NO892319 A NO 892319A NO 892319 L NO892319 L NO 892319L
Authority
NO
Norway
Prior art keywords
leucocytes
trauma
procedure
bodies under
inhibit influence
Prior art date
Application number
NO89892319A
Other languages
English (en)
Norwegian (no)
Other versions
NO892319D0 (no
Inventor
Samuel D Wright
Elaine I Tuomanen
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of NO892319D0 publication Critical patent/NO892319D0/no
Publication of NO892319L publication Critical patent/NO892319L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO89892319A 1988-06-07 1989-06-06 Fremgangsmaate for aa inhibere tilstroemning av leucocytter til organer under sepsis eller annen trauma. NO892319L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20403788A 1988-06-07 1988-06-07
US07/331,450 US5147637A (en) 1988-06-07 1989-03-31 Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma

Publications (2)

Publication Number Publication Date
NO892319D0 NO892319D0 (no) 1989-06-06
NO892319L true NO892319L (no) 1989-12-08

Family

ID=26899117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89892319A NO892319L (no) 1988-06-07 1989-06-06 Fremgangsmaate for aa inhibere tilstroemning av leucocytter til organer under sepsis eller annen trauma.

Country Status (10)

Country Link
US (1) US5147637A (fr)
EP (1) EP0346078A3 (fr)
JP (1) JPH02104534A (fr)
KR (1) KR910000184A (fr)
AU (1) AU620100B2 (fr)
DK (1) DK278589A (fr)
FI (1) FI892793A7 (fr)
IL (1) IL90529A (fr)
NO (1) NO892319L (fr)
PT (1) PT90775B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0432249B1 (fr) 1989-06-02 1996-09-25 The Johns Hopkins University School Of Medicine Anticorps monoclonaux contre la chaine beta de recepteurs d'adhesion de leucocytes, procede de production de ces anticorps et utilisation
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
DE4019024A1 (de) * 1990-06-14 1991-12-19 Bayer Ag Verwendung der efomycine a, e und g als entzuendungshemmende mittel
JPH06500555A (ja) * 1990-08-27 1994-01-20 カイロン　コーポレイション 病気の処置のためのペプチドの薬物
WO1992004034A1 (fr) * 1990-08-31 1992-03-19 Boehringer Ingelheim Pharmaceuticals, Inc. Procede traitant les chocs endotoxiniques au moyen d'anticorps anti-adhesion
EP0565642A1 (fr) * 1991-01-11 1993-10-20 Repligen Corporation Procede de prevention des lesions inflammatoires
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
ATE145827T1 (de) * 1991-04-03 1996-12-15 Boehringer Ingelheim Pharma Verfahren zur hemmung der sauerstofftoxizität in den lungen
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU2777092A (en) * 1991-10-04 1993-05-03 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Treatment of ocular inflammation by blockage of cell adhesion molecules
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
CA2119128C (fr) * 1992-07-16 2000-05-30 Lynn M. Rose Soulagement des symptomes associes aux etats inflammatoires aigus
CA2140933A1 (fr) * 1992-08-21 1994-02-22 Paula M. Jardieu Methode de traitement pour les atteintes dues a la molecule lfa-1
WO1994012214A1 (fr) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Anticorps humanises reagissant avec la cd-18
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000056363A1 (fr) 1999-03-19 2000-09-28 Genentech, Inc. Traitement de troubles associes au lfa-1 par augmentation des doses d'antagoniste de lfa-1
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
WO2001002009A1 (fr) * 1999-07-06 2001-01-11 Johns Hopkins University Methode d'inhibition de l'angiospasme et composition a cet effet
AU4574501A (en) 2000-03-17 2001-10-03 Millennium Pharm Inc Method of inhibiting stenosis and restenosis
JP2004507448A (ja) * 2000-03-18 2004-03-11 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 狭窄症関連疾患を抑制するｃｄ−１８結合抗体
EP1756163A2 (fr) 2004-06-09 2007-02-28 Genentech, Inc. Procede de traitement du granulome annulaire ou sarcoide
WO2008101133A2 (fr) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Procédés d'utilisation de gènes et de variants génétiques pour prévoir ou diagnostiquer une affection abdominale inflammatoire
CA3204588A1 (fr) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methodes de diagnostic et de traitement de la maladie de crohn
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (fr) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Procédés d’utilisation de gènes de la voie il17rd et il23-il17 pour diagnostiquer la maladie de crohn
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (fr) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Méthodes de prédiction de colite ulcéreuse réfractaire aux traitements (mr-uc) nécessitant une colectomie
ES2705244T3 (es) 2010-06-16 2019-03-22 Inflammatory Response Res Inc Levocetirizina y montelukast para el tratamiento de la gripe y del resfriado común
EP2968309A4 (fr) 2013-03-13 2016-08-31 Inflammatory Response Res Inc Utilisation de lévocétirizine et de montelukast dans le traitement de la vascularite
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (fr) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature de la voie de signalisation de tl1a (tnfsf15)
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2021236518A1 (fr) 2020-05-19 2021-11-25 IRR, Inc. Lévocétirizine et montélukast utilisés dans le traitement du sepsis et de ses symptômes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
WO1988006592A1 (fr) * 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Clonage de lfa-1
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy

Also Published As

Publication number Publication date
JPH02104534A (ja) 1990-04-17
FI892793L (fi) 1989-12-08
AU3608489A (en) 1989-12-14
AU620100B2 (en) 1992-02-13
US5147637A (en) 1992-09-15
IL90529A (en) 1994-01-25
DK278589A (da) 1989-12-08
FI892793A0 (fi) 1989-06-07
FI892793A7 (fi) 1989-12-08
EP0346078A3 (fr) 1991-03-20
IL90529A0 (en) 1990-01-18
NO892319D0 (no) 1989-06-06
PT90775B (pt) 1994-11-30
PT90775A (pt) 1989-12-29
KR910000184A (ko) 1991-01-29
DK278589D0 (da) 1989-06-07
EP0346078A2 (fr) 1989-12-13

Similar Documents

Publication Publication Date Title
NO892319D0 (no) Fremgangsmaate for aa inhibere tilstroemning av leucocytter til organer under sepsis eller annen trauma.
MX7194E (es) Procedimiento para aumentar el contenido de solidos de azucar de las frutas
DK454985A (da) Frigoerelsessystem til to eller flere aktive stoffer
NL185088B (nl) Kleefmiddelsamenstelling en samengestelde struktuur van substraten en kleefmiddel.
BR8504457A (pt) Processos para a preparacao de um composto e de uma composicao para combater infeccoes ou infestacoes
DK197482A (da) Sugeindretning saasom en dentalaspirator eller en suger
NO152456C (no) Fremgangsmaate til aa hindre marin begroning av konstruksjoner
DK52688A (da) Gastaet roerforbindelse til forings- og/eller stigroer
CA950218A (en) Process and system for increasing load-bearing capacity of soil
FI875079A7 (fi) Isosyanaatti-karboksyyliryhmiä sisältävätrasvahappoyhdisteet selluloosakoosteiden valmistamiseksi.
NO163690C (no) Fremgangsmaate for fremstilling av to kvaliteter av propylen.
NO873902D0 (no) Fremgangsmaate for aa forbedre overflaters evne til aa motstaa isdannelse eller aa fjerne allerede dannet is.
EP0808629A4 (fr) Preparation de sucralfate
NO151556C (no) Marineplattform innrettet for aa muliggjoere detektering av eventuelle sprekker
FI861530A0 (fi) Uppslamning av gips eller krita i vatten.
NO891851D0 (no) Fremgangsmaate for fremstilling av monokrystallinske aluminiumoksydkorn.
SE7607124L (sv) Balk for uppbering av deck eller pallar
NO162341C (no) Fremgangsmaate for skjellettisomerisering av lineaere olefiner til forgrenede olefiner.
NO894304D0 (no) Fremgangsmaate til fremstilling av sukkerfosfater og -sulfonater av epipodofyllotoksinglukosider.
FI792548A7 (fi) Fenyyliguanidiinisulfonihappoesterien monokarboksylaatteja, menetelmiä niiden valmistamiseksi ja niiden käytlääkeianeina.
DE3761787D1 (de) System zur bestimmung der fluggeschwindigkeit von hubschraubern.
NO162340C (no) Fremgangsmaate for skjellettisomerisering av lineaere olefiner til forgrenede olefiner.
FI875109A0 (fi) Apparatur foer uppfoerande av vaeder- och/eller kamoufleringsskjul.
NO863735D0 (no) Fremgangsmaate for fremstilling av ranitidin eller syreaddisjonssalter derav.
NO164964C (no) Fremgangsmaate for fremstilling av lignocelluloseholdige stoepte sammensatte eller kompositt-produkter.